+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The results of long-term permixon treatment in patients with symptoms of lower urinary tracts dysfunction due to benign prostatic hyperplasia

The results of long-term permixon treatment in patients with symptoms of lower urinary tracts dysfunction due to benign prostatic hyperplasia

Urologiia 2004(2): 3-7

The trial enrolled 155 patients (mean age 65 years) with documented benign prostatic hyperplasia and lower urinary tracts symptoms (LUTS) (IPSS > 6). All the patients received permixon in a dose 160 mg twice a day for 2 years. The data on 130 patients eligible for assessment were processed statistically by dynamics of IPSS, quality of life (QOL), index of sexual function (MSF-4), size of the prostate, urodynamic and biological parameters which were estimated in 6 (V6), 12 (V12), 18 (V18) and 24 months (V24). Clinical examination with registration of all side effects was made each 3 months. Permixon was found to noticeably reduce IPSS and QOL and increase maximal urine flow speed. The size of the prostate diminished insignificantly. Sexual function remained unchanged for 1 year and improved markedly within the second year (p = 0.001). Permixon had no effect on the level of prostate-specific antigen. Plasma hormones (testosterone, DHT, estradiol, LH, androstendion) did not change. Nine patients developed 10 side effects but they were unrelated to the treatment.

(PDF emailed within 1 workday: $29.90)

Accession: 050716555

Download citation: RISBibTeXText

PMID: 15114742

Related references

The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study. Journal of Urology 173(3): 903-907, 2005

Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate 75(16): 1857-1867, 2016

A Study of the Role of 180W XPS Lithium Triborate Laser in the Treatment of Patients With Lower Urinary Tracts Symptoms Due to Benign Prostatic Hyperplasia. Journal of Lasers in Medical Sciences 9(4): 261-267, 2019

Short-term efficacy and long-term compliance/treatment failure of the alpha 1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Scandinavian Journal of Urology and Nephrology 41(5): 422-429, 2007

Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica 49(4): 189-193, 2003

Comparison of the Effects of Hexanic Extract of Serenoa repens (Permixon) and Tamsulosin on Inflammatory Biomarkers in the Treatment of Benign Prostatic Hyperplasia-Related Lower Urinary Tract Symptoms. European Urology Supplements 14(9): E1470-E1474, 2015

Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride. European Urology 48(2): 269-276, 2005

Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology 73(1): 90-94, 2008

Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Journal of Urology 170(2 Pt 1): 498-502, 2003

Long-term results of three different minimally invasive therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: comparison at a single institute. International Journal of Urology 14(4): 326-330, 2007

Lower urinary tract symptoms, benign prostatic hyperplasia/benign prostatic enlargement and erectile dysfunction: are these conditions related to vascular dysfunction?. International Journal of Urology 21(9): 856-864, 2015

Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials. European Urology Focus 2(5): 553-561, 2017

Long-term efficacy and safety of tamsulosin hydrochloride for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: data from China. Chinese Medical Journal 124(1): 56-60, 2011

Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study. Journal of Sexual Medicine 11(2): 498-505, 2014

Treatment of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. Aging Male 21(4): 272-280, 2018